Evidence map›Paper›PMID 24090432›Full record

ReviewHarm reduction journal2013

A fresh look at tobacco harm reduction: the case for the electronic cigarette.

Riccardo Polosa, Brad Rodu, Pasquale Caponnetto, Marilena Maglia, Cirino Raciti

3 registry-linked trialsAbstract readReview
In one paragraph

Review in Harm reduction journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 100 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03050853 nacompletednot on this mapstarted 2017, after this paper: background citation

The Appeal and Impact of E-cigarettes in Smokers With Serious Mental Illness

TypeinterventionalSponsorDartmouth-Hitchcock Medical CenterRan2017 to 2021Enrolled240ConditionsTobacco Dependence, Schizophrenia, Bipolar Disorder, Schizoaffective DisorderArmsE-cigarette
NCT04231838 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study

TypeinterventionalSponsorEclat Srl.Ran2021 to 2026Enrolled576ConditionsCardiovascular Risk Factor, Diabetes Mellitus, Type 2ArmsTOBACCO CIGARETTES, COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
NCT04649645 nacompletednot on this mapstarted 2021, after this paper: background citation

International Randomized Controlled Trial Evaluating Changes in Oral Health in Smokers After Switching to Combustion-Free Nicotine Delivery Systems: SMILE Study Protocol

TypeinterventionalSponsorEclat Srl.Ran2021 to 2024Enrolled460ConditionsGingivitis, Periodontal DiseasesArmsTOBACCO CIGARETTES, COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS), NOT SMOKING
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. The Importance of Conditioned Stimuli in Cigarette and E-Cigarette Craving Reduction by E-Cigarettes.International journal of environmental research and public health · 2017
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Riccardo PolosaPresidio G, Rodolico - Unità Operativa di Medicina Interna e Medicina d'Urgenza, Centro per la Prevenzione e Cura del Tabagismo (CPCT), Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", Università di Catania, Catania, Italy. polosa@unict.it.
Brad Rodu
Pasquale Caponnetto
Marilena Maglia
Cirino Raciti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smokers of any age can reap substantial health benefits by quitting. In fact, no other single public health effort is likely to achieve a benefit comparable to large-scale smoking cessation. Surveys document that most smokers would like to quit, and many have made repeated efforts to do so. However, conventional smoking cessation approaches require nicotine addicted smokers to abstain from tobacco and nicotine entirely. Many smokers are unable--or at least unwilling--to achieve this goal, and so they continue smoking in the face of impending adverse health consequences. In effect, the status quo in smoking cessation presents smokers with just two unpleasant alternatives: quit or suffer the harmful effects of continuing smoking. But, there is a third choice for smokers: tobacco harm reduction. It involves the use of alternative sources of nicotine, including modern smokeless tobacco products like snus and the electronic cigarette (E-cig), or even pharmaceutical nicotine products, as a replacement for smoking. E-cigs might be the most promising product for tobacco harm reduction to date, because, besides delivering nicotine vapour without the combustion products that are responsible for nearly all of smoking's damaging effect, they also replace some of the rituals associated with smoking behaviour. Thus it is likely that smokers who switch to E-cigs will achieve large health gains. The focus of this article is on the health effects of using an E-cig, with consideration given to the acceptability, safety and effectiveness of this product as a long-term substitute for smoking.

Indexed as

Harm ReductionSmoking PreventionClinical Trials as TopicElectronicsHumansSecondary PreventionSmoking CessationTobacco, SmokelessTobacco Use Cessation Devices

Identifiers

PMID24090432
PMCPMC3850892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.